Core Insights - Hims & Hers Health Inc. has decided to cease offering its compounded semaglutide pill shortly after its launch [1][2] Group 1: Company Decision - The decision to stop offering the $49 version of Novo Nordisk's Wegovy was made following constructive conversations with industry stakeholders [2] - Hims & Hers remains committed to providing safe, affordable, and personalized healthcare to millions of Americans despite this decision [3] Group 2: Regulatory Environment - The FDA has warned of steps to restrict GLP-1 active pharmaceutical ingredients intended for non-FDA-approved compounded drugs, which includes products from Hims & Hers [4] - The Department of Health and Human Services has referred Hims & Hers to the Department of Justice for investigation regarding potential violations of the Federal Food, Drug, and Cosmetic Act [5] Group 3: Market Reaction and Legal Issues - The introduction of the pill initially led to a surge in Hims & Hers stock, reaching new highs [6] - However, the launch faced legal threats from Novo Nordisk, which accused Hims & Hers of violating laws related to the mass sale of compounded drugs and engaging in deceptive marketing practices [7]